Control of Cutaneous Leishmaniasis (CL) in the Americas largely relies on passive case detection and ambulatory treatment without comprehensive follow-up. Information on clinical response and adverse drug reactions under the standard of care are neither routinely obtained nor reported. Passive case detection is particularly inefficient in the vast rural areas of transmission where dispersed populations have limited access to diagnosis through health systems. Despite some recent reports of treatment failures, the logistical demands of endemic areas, and the toxicity of the recommended parenterally administered drugs, have contributed to the virtual absence of information on their routine effectiveness, as opposed to efficacy. The overall goal of the proposed project is to estimate the hidden burden of cutaneous leishmaniasis by predictive risk mapping and quantifying underestimation cases and effectiveness of standard-of-care treatment. We will integrate a comprehensive assessment of under-reporting and under-ascertainment through case detection based on passive and active surveillance by community-based surveillance and risk mapping and we will implement mHealth tools for quantifying treatment effectiveness under routine clinical practice conditions. This working framework will allow us to extend mHealth surveillance to treatment follow-up and effectiveness estimation in CL. To achieve this, we will develop the following specific aims: 1) Estimate under-reporting and under-ascertainment of CL using mHealth assisted active case detection, chain-referral sampling, and community-based surveillance. 2) Develop a model, based on remote sensing and vector niches, for predicting risk of cutaneous leishmaniasis, and estimate its ability to identify high-risk sites 3) Estimate the effectiveness of the standard treatment for CL in three municipalities supported with mHealth tools managed by leading participants of the community. Results from this project will provide the evidence base for implementation of community based active case detection and referral for standard of care treatment using novel mHealth tools that can be implemented at the community level. Early diagnosis and treatment will reduce the burden of disease, and its physical and social consequences.

Public Health Relevance

Control of cutaneous leishmaniasis in the Americas generally relies on affected individuals presenting themselves to health services. Especially in remote rural areas, this is not always feasible, and it is thought that the number of unrecognized and untreated cases could be half the total, or even more. In this project we aim to estimate the under-reporting and under-ascertainment by a mixture of ecological mapping and community-based outreach strategies aided by mobile phone apps, aiming towards community-based strategies for active case detection, treatment and follow-up.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI129910-04
Application #
9897622
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
4
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Centro Internacional (Cideim)
Department
Type
DUNS #
880287946
City
Cali
State
Country
Colombia
Zip Code
760031